Baseline characteristics of non-ischaemic dilated cardiomyopathy patients with and without cardiac events in derivation cohort
| . | All patients (n: 1000) . | Primary endpoint (−) (n: 928) . | Primary endpoint (+) (n: 72) . | P-value . | Secondary endpoint (−) (n: 907) . | Secondary endpoint (+) (n: 93) . | P-value . |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Age (years) | 56.7 ± 14.2 | 56.2 ± 11.4 | 63.4 ± 13.5 | <0.001 | 56.7 ± 14.2 | 56.9 ± 13.9 | 0.907 |
| Male | 686 (68.6%) | 635 (68.4%) | 51 (70.8%) | 0.672 | 609 (67.1%) | 77 (82.8%) | 0.002 |
| BSA (m2) | 1.90 ± 0.24 | 1.90 ± 0.24 | 1.89 ± 0.26 | 0.797 | 1.90 ± 0.24 | 1.93 ± 0.20 | 0.254 |
| Cardiovascular risk factor | |||||||
| Family history | 301 (30.1%) | 282 (30.4%) | 19 (26.4%) | 0.476 | 274 (30.2%) | 27 (29.0%) | 0.814 |
| Smoking history | 338 (34.0%) | 322 (34.9%) | 16 (22.2%) | 0.028 | 315 (35.0%) | 23 (24.7%) | 0.047 |
| Hypertension | 404 (40.7%) | 373 (40.5%) | 31 (43.1%) | 0.676 | 404 (40.7%) | 37 (39.8%) | 0.846 |
| Hyperlipidaemia | 326 (32.6%) | 307 (33.1%) | 19 (26.4%) | 0.243 | 298 (32.9%) | 28 (30.1%) | 0.590 |
| Diabetes | 147 (14.7%) | 131 (14.1%) | 16 (22.2%) | 0.061 | 133 (14.7%) | 14 (15.1%) | 0.919 |
| NYHA class | |||||||
| I–II | 808 (80.8%) | 749 (80.7%) | 59 (81.9%) | 0.798 | 735 (81.0%) | 73 (78.5%) | 0.553 |
| III–IV | 192 (19.2%) | 179 (19.3%) | 13 (18.1%) | 172 (19.0%) | 20 (21.5%) | ||
| Medical therapy | |||||||
| β-Blockers | 821 (82.1%) | 765 (82.4%) | 56 (77.8%) | 0.321 | 732 (80.7%) | 89 (95.7%) | <0.001 |
| Ivabradine | 51 (5.1%) | 50 (5.4%) | 1 (1.4%) | 0.170 | 47 (5.2%) | 4 (4.3%) | 1.00 |
| ACE-inhibitors/AT1 blockers | 846 (84.6%) | 787 (84.8%) | 59 (81.9%) | 0.517 | 763 (84.1%) | 83 (89.3%) | 0.192 |
| Diuretics | 632 (63.2%) | 578 (62.3%) | 54 (75.0%) | 0.031 | 564 (62.2%) | 68 (73.1%) | 0.037 |
| Calcium-blockers | 37 (3.7%) | 32 (3.5%) | 5 (6.9%) | 0.130 | 35 (3.9%) | 2 (2.2%) | 0.569 |
| Anti-thrombotic agents | 312 (17.4%) | 290 (31.3%) | 22 (30.6%) | 0.902 | 289 (31.9%) | 23 (24.7%) | 0.157 |
| Anticoagulant therapy | 174 (20.3%) | 156 (16.8%) | 18 (25.0%) | 0.077 | 155 (17.1%) | 19 (20.4%) | 0.418 |
| Nitrates | 61 (6.1%) | 51 (5.5%) | 10 (13.9%) | 0.004 | 55 (6.1%) | 6 (6.5%) | 0.882 |
| Statins | 300 (30.0%) | 277 (29.9%) | 23 (31.9%) | 0.709 | 270 (29.8%) | 30 (32.3%) | 0.618 |
| Amiodarone/other antiarrhythmics | 167 (16.7%) | 152 (16.4%) | 15 (20.8%) | 0.329 | 145 (16.0%) | 22 (23.7%) | 0.059 |
| Device implantation and treatment during the follow-up | |||||||
| ICD/CRT-D implantation | 321 (32.1%) | 306 (33%) | 15 (20.8%) | 0.031 | 245 (27.1%) | 76 (81.7%) | <0.001 |
| . | All patients (n: 1000) . | Primary endpoint (−) (n: 928) . | Primary endpoint (+) (n: 72) . | P-value . | Secondary endpoint (−) (n: 907) . | Secondary endpoint (+) (n: 93) . | P-value . |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Age (years) | 56.7 ± 14.2 | 56.2 ± 11.4 | 63.4 ± 13.5 | <0.001 | 56.7 ± 14.2 | 56.9 ± 13.9 | 0.907 |
| Male | 686 (68.6%) | 635 (68.4%) | 51 (70.8%) | 0.672 | 609 (67.1%) | 77 (82.8%) | 0.002 |
| BSA (m2) | 1.90 ± 0.24 | 1.90 ± 0.24 | 1.89 ± 0.26 | 0.797 | 1.90 ± 0.24 | 1.93 ± 0.20 | 0.254 |
| Cardiovascular risk factor | |||||||
| Family history | 301 (30.1%) | 282 (30.4%) | 19 (26.4%) | 0.476 | 274 (30.2%) | 27 (29.0%) | 0.814 |
| Smoking history | 338 (34.0%) | 322 (34.9%) | 16 (22.2%) | 0.028 | 315 (35.0%) | 23 (24.7%) | 0.047 |
| Hypertension | 404 (40.7%) | 373 (40.5%) | 31 (43.1%) | 0.676 | 404 (40.7%) | 37 (39.8%) | 0.846 |
| Hyperlipidaemia | 326 (32.6%) | 307 (33.1%) | 19 (26.4%) | 0.243 | 298 (32.9%) | 28 (30.1%) | 0.590 |
| Diabetes | 147 (14.7%) | 131 (14.1%) | 16 (22.2%) | 0.061 | 133 (14.7%) | 14 (15.1%) | 0.919 |
| NYHA class | |||||||
| I–II | 808 (80.8%) | 749 (80.7%) | 59 (81.9%) | 0.798 | 735 (81.0%) | 73 (78.5%) | 0.553 |
| III–IV | 192 (19.2%) | 179 (19.3%) | 13 (18.1%) | 172 (19.0%) | 20 (21.5%) | ||
| Medical therapy | |||||||
| β-Blockers | 821 (82.1%) | 765 (82.4%) | 56 (77.8%) | 0.321 | 732 (80.7%) | 89 (95.7%) | <0.001 |
| Ivabradine | 51 (5.1%) | 50 (5.4%) | 1 (1.4%) | 0.170 | 47 (5.2%) | 4 (4.3%) | 1.00 |
| ACE-inhibitors/AT1 blockers | 846 (84.6%) | 787 (84.8%) | 59 (81.9%) | 0.517 | 763 (84.1%) | 83 (89.3%) | 0.192 |
| Diuretics | 632 (63.2%) | 578 (62.3%) | 54 (75.0%) | 0.031 | 564 (62.2%) | 68 (73.1%) | 0.037 |
| Calcium-blockers | 37 (3.7%) | 32 (3.5%) | 5 (6.9%) | 0.130 | 35 (3.9%) | 2 (2.2%) | 0.569 |
| Anti-thrombotic agents | 312 (17.4%) | 290 (31.3%) | 22 (30.6%) | 0.902 | 289 (31.9%) | 23 (24.7%) | 0.157 |
| Anticoagulant therapy | 174 (20.3%) | 156 (16.8%) | 18 (25.0%) | 0.077 | 155 (17.1%) | 19 (20.4%) | 0.418 |
| Nitrates | 61 (6.1%) | 51 (5.5%) | 10 (13.9%) | 0.004 | 55 (6.1%) | 6 (6.5%) | 0.882 |
| Statins | 300 (30.0%) | 277 (29.9%) | 23 (31.9%) | 0.709 | 270 (29.8%) | 30 (32.3%) | 0.618 |
| Amiodarone/other antiarrhythmics | 167 (16.7%) | 152 (16.4%) | 15 (20.8%) | 0.329 | 145 (16.0%) | 22 (23.7%) | 0.059 |
| Device implantation and treatment during the follow-up | |||||||
| ICD/CRT-D implantation | 321 (32.1%) | 306 (33%) | 15 (20.8%) | 0.031 | 245 (27.1%) | 76 (81.7%) | <0.001 |
NYHA, New York Heart Association; ICD, implantable cardioverter-defibrillator.
Baseline characteristics of non-ischaemic dilated cardiomyopathy patients with and without cardiac events in derivation cohort
| . | All patients (n: 1000) . | Primary endpoint (−) (n: 928) . | Primary endpoint (+) (n: 72) . | P-value . | Secondary endpoint (−) (n: 907) . | Secondary endpoint (+) (n: 93) . | P-value . |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Age (years) | 56.7 ± 14.2 | 56.2 ± 11.4 | 63.4 ± 13.5 | <0.001 | 56.7 ± 14.2 | 56.9 ± 13.9 | 0.907 |
| Male | 686 (68.6%) | 635 (68.4%) | 51 (70.8%) | 0.672 | 609 (67.1%) | 77 (82.8%) | 0.002 |
| BSA (m2) | 1.90 ± 0.24 | 1.90 ± 0.24 | 1.89 ± 0.26 | 0.797 | 1.90 ± 0.24 | 1.93 ± 0.20 | 0.254 |
| Cardiovascular risk factor | |||||||
| Family history | 301 (30.1%) | 282 (30.4%) | 19 (26.4%) | 0.476 | 274 (30.2%) | 27 (29.0%) | 0.814 |
| Smoking history | 338 (34.0%) | 322 (34.9%) | 16 (22.2%) | 0.028 | 315 (35.0%) | 23 (24.7%) | 0.047 |
| Hypertension | 404 (40.7%) | 373 (40.5%) | 31 (43.1%) | 0.676 | 404 (40.7%) | 37 (39.8%) | 0.846 |
| Hyperlipidaemia | 326 (32.6%) | 307 (33.1%) | 19 (26.4%) | 0.243 | 298 (32.9%) | 28 (30.1%) | 0.590 |
| Diabetes | 147 (14.7%) | 131 (14.1%) | 16 (22.2%) | 0.061 | 133 (14.7%) | 14 (15.1%) | 0.919 |
| NYHA class | |||||||
| I–II | 808 (80.8%) | 749 (80.7%) | 59 (81.9%) | 0.798 | 735 (81.0%) | 73 (78.5%) | 0.553 |
| III–IV | 192 (19.2%) | 179 (19.3%) | 13 (18.1%) | 172 (19.0%) | 20 (21.5%) | ||
| Medical therapy | |||||||
| β-Blockers | 821 (82.1%) | 765 (82.4%) | 56 (77.8%) | 0.321 | 732 (80.7%) | 89 (95.7%) | <0.001 |
| Ivabradine | 51 (5.1%) | 50 (5.4%) | 1 (1.4%) | 0.170 | 47 (5.2%) | 4 (4.3%) | 1.00 |
| ACE-inhibitors/AT1 blockers | 846 (84.6%) | 787 (84.8%) | 59 (81.9%) | 0.517 | 763 (84.1%) | 83 (89.3%) | 0.192 |
| Diuretics | 632 (63.2%) | 578 (62.3%) | 54 (75.0%) | 0.031 | 564 (62.2%) | 68 (73.1%) | 0.037 |
| Calcium-blockers | 37 (3.7%) | 32 (3.5%) | 5 (6.9%) | 0.130 | 35 (3.9%) | 2 (2.2%) | 0.569 |
| Anti-thrombotic agents | 312 (17.4%) | 290 (31.3%) | 22 (30.6%) | 0.902 | 289 (31.9%) | 23 (24.7%) | 0.157 |
| Anticoagulant therapy | 174 (20.3%) | 156 (16.8%) | 18 (25.0%) | 0.077 | 155 (17.1%) | 19 (20.4%) | 0.418 |
| Nitrates | 61 (6.1%) | 51 (5.5%) | 10 (13.9%) | 0.004 | 55 (6.1%) | 6 (6.5%) | 0.882 |
| Statins | 300 (30.0%) | 277 (29.9%) | 23 (31.9%) | 0.709 | 270 (29.8%) | 30 (32.3%) | 0.618 |
| Amiodarone/other antiarrhythmics | 167 (16.7%) | 152 (16.4%) | 15 (20.8%) | 0.329 | 145 (16.0%) | 22 (23.7%) | 0.059 |
| Device implantation and treatment during the follow-up | |||||||
| ICD/CRT-D implantation | 321 (32.1%) | 306 (33%) | 15 (20.8%) | 0.031 | 245 (27.1%) | 76 (81.7%) | <0.001 |
| . | All patients (n: 1000) . | Primary endpoint (−) (n: 928) . | Primary endpoint (+) (n: 72) . | P-value . | Secondary endpoint (−) (n: 907) . | Secondary endpoint (+) (n: 93) . | P-value . |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Age (years) | 56.7 ± 14.2 | 56.2 ± 11.4 | 63.4 ± 13.5 | <0.001 | 56.7 ± 14.2 | 56.9 ± 13.9 | 0.907 |
| Male | 686 (68.6%) | 635 (68.4%) | 51 (70.8%) | 0.672 | 609 (67.1%) | 77 (82.8%) | 0.002 |
| BSA (m2) | 1.90 ± 0.24 | 1.90 ± 0.24 | 1.89 ± 0.26 | 0.797 | 1.90 ± 0.24 | 1.93 ± 0.20 | 0.254 |
| Cardiovascular risk factor | |||||||
| Family history | 301 (30.1%) | 282 (30.4%) | 19 (26.4%) | 0.476 | 274 (30.2%) | 27 (29.0%) | 0.814 |
| Smoking history | 338 (34.0%) | 322 (34.9%) | 16 (22.2%) | 0.028 | 315 (35.0%) | 23 (24.7%) | 0.047 |
| Hypertension | 404 (40.7%) | 373 (40.5%) | 31 (43.1%) | 0.676 | 404 (40.7%) | 37 (39.8%) | 0.846 |
| Hyperlipidaemia | 326 (32.6%) | 307 (33.1%) | 19 (26.4%) | 0.243 | 298 (32.9%) | 28 (30.1%) | 0.590 |
| Diabetes | 147 (14.7%) | 131 (14.1%) | 16 (22.2%) | 0.061 | 133 (14.7%) | 14 (15.1%) | 0.919 |
| NYHA class | |||||||
| I–II | 808 (80.8%) | 749 (80.7%) | 59 (81.9%) | 0.798 | 735 (81.0%) | 73 (78.5%) | 0.553 |
| III–IV | 192 (19.2%) | 179 (19.3%) | 13 (18.1%) | 172 (19.0%) | 20 (21.5%) | ||
| Medical therapy | |||||||
| β-Blockers | 821 (82.1%) | 765 (82.4%) | 56 (77.8%) | 0.321 | 732 (80.7%) | 89 (95.7%) | <0.001 |
| Ivabradine | 51 (5.1%) | 50 (5.4%) | 1 (1.4%) | 0.170 | 47 (5.2%) | 4 (4.3%) | 1.00 |
| ACE-inhibitors/AT1 blockers | 846 (84.6%) | 787 (84.8%) | 59 (81.9%) | 0.517 | 763 (84.1%) | 83 (89.3%) | 0.192 |
| Diuretics | 632 (63.2%) | 578 (62.3%) | 54 (75.0%) | 0.031 | 564 (62.2%) | 68 (73.1%) | 0.037 |
| Calcium-blockers | 37 (3.7%) | 32 (3.5%) | 5 (6.9%) | 0.130 | 35 (3.9%) | 2 (2.2%) | 0.569 |
| Anti-thrombotic agents | 312 (17.4%) | 290 (31.3%) | 22 (30.6%) | 0.902 | 289 (31.9%) | 23 (24.7%) | 0.157 |
| Anticoagulant therapy | 174 (20.3%) | 156 (16.8%) | 18 (25.0%) | 0.077 | 155 (17.1%) | 19 (20.4%) | 0.418 |
| Nitrates | 61 (6.1%) | 51 (5.5%) | 10 (13.9%) | 0.004 | 55 (6.1%) | 6 (6.5%) | 0.882 |
| Statins | 300 (30.0%) | 277 (29.9%) | 23 (31.9%) | 0.709 | 270 (29.8%) | 30 (32.3%) | 0.618 |
| Amiodarone/other antiarrhythmics | 167 (16.7%) | 152 (16.4%) | 15 (20.8%) | 0.329 | 145 (16.0%) | 22 (23.7%) | 0.059 |
| Device implantation and treatment during the follow-up | |||||||
| ICD/CRT-D implantation | 321 (32.1%) | 306 (33%) | 15 (20.8%) | 0.031 | 245 (27.1%) | 76 (81.7%) | <0.001 |
NYHA, New York Heart Association; ICD, implantable cardioverter-defibrillator.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
